Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
The occurrence of multiple myeloma and chronic lymphocytic leukemia in the same patient is very uncommon. The immunomodulatory agent lenalidomide has been shown to have high response rates in multiple myeloma and appears to be quite active in advanced CLL. We report two patients with concurrent CLL and MM who were both treated successfully with lenalidomide.
Srinivasan
Sridhar
S
Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, HWCRB-4th Floor, 4100 John R, Detroit, MI 48201, USA. srinivas@karmanos.org
Schiffer
Charles A
CA
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000503:physiopathology; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000503:physiopathology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide